Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xintela ABFRA:1XT -4.76%8 3-Year EBITDA Growth Rate is 42.90% as of Mar. 2026, which is 2045% above its 10-year median of 2.00. GuruFocus rates FRA:1XT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Xintela AB ranks better than 80.3% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 42.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 34.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 16.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Xintela AB was 44.60% per year. The lowest was -79.50% per year. And the median was 2.00% per year.
Xintela AB (FRA:1XT) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Xintela AB 3-Year EBITDA Growth Rate Related Terms
FRA:1XT vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Xintela AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xintela AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xintela AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Xintela AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 42.90% mean?
Xintela AB (FRA:1XT) has a 3-Year EBITDA Growth Rate of 42.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Xintela AB and its competitors. This is 2045% above median its historical median of 2.00. According to the industry distribution chart, Xintela AB ranks #222 out of 1127 companies in the Biotechnology industry, placing it in the top 19.7%.
Is Xintela AB's 3-Year EBITDA Growth Rate too high?
Xintela AB's current 3-Year EBITDA Growth Rate of 42.90% is 2045% above median its 10-year median of 2.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Xintela AB's value of 42.90% is 187.9% above this industry median. Based on the distribution chart, Xintela AB ranks #222 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xintela AB ranks #222 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Xintela AB in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Xintela AB's value of 42.90% is 187.9% above this benchmark. While the company's 10-year median is 2.00 vs. the industry median of 14.90, Xintela AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xintela AB's current 3-Year EBITDA Growth Rate of 42.90% is 187.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Xintela AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xintela AB's current 3-Year EBITDA Growth Rate is 42.90%, which is 2045% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (FRA:1XT) has a current 3-Year EBITDA Growth Rate of 42.90%. The current 3-Year EBITDA Growth Rate is 42.90%, which is 2045% above median its 10-year median of 2.00 and 187.9% above the Biotechnology industry median of 14.90. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Xintela AB (FRA:1XT), the current 3-Year EBITDA Growth Rate is 42.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score
Get the complete analysis for FRA:1XT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1XT has been successfully added to your 
